WCLC 2025 - Posters & ePosters-P1.17.53 Real-World Experience With EGFR-Positive NSCLC in Resource-Limited Settings: A Decade-Long Single Center Study From Jordan

P1.17.53 Real-World Experience With EGFR-Positive NSCLC in Resource-Limited Settings: A Decade-Long Single Center Study From Jordan

Back to course

Pdf Summary

This study presents a decade-long retrospective analysis (2014-2024) of 200 patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated at King Hussein Cancer Center in Jordan, a resource-limited setting. The investigation focused on clinical and molecular features, treatments, response rates, and survival outcomes, providing valuable real-world data from the Middle East and North Africa (MENA) region where such evidence is scarce.<br /><br />Results show a median follow-up of about 27 months. Patients receiving first-line gefitinib, a first-generation tyrosine kinase inhibitor (TKI), had a median progression-free survival (PFS) of 10 months. When considering all lines of therapy, median PFS was 10 months for gefitinib and 14 months for osimertinib, a third-generation TKI. Overall survival (OS) across all patients treated with any EGFR TKI was 25 months, consistent with published international literature despite resource constraints.<br /><br />Significantly, the presence of liver metastases was associated with worse outcomes in both PFS and OS regardless of TKI generation. The study highlights the importance of access to newer third-generation TKIs like osimertinib in low- and middle-income countries (LMICs), where first-generation TKIs remain the most used due to cost and availability issues.<br /><br />In conclusion, Jordanian patients with EGFR-mutated NSCLC experience long survival when treated with EGFR TKIs, aligning with global data. This underscores the critical need to improve access to advanced therapies in resource-limited settings to optimize patient outcomes. The study enhances understanding of lung cancer management in LMICs and supports policy changes to expand access to effective targeted therapies.

Asset Subtitle

Kamal Al-rabi

Meta Tag

Speaker Kamal Al-rabi

Topic Global Health, Health Services, and Health Economics

Keywords

EGFR-mutated NSCLC

non-small cell lung cancer

King Hussein Cancer Center

Jordan

tyrosine kinase inhibitors

gefitinib

osimertinib

progression-free survival

overall survival

liver metastases